Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01514981 · ClinicalTrials.gov registry record · Phase 1
AMG 761 in Adults With Asthma
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01514981: Clinical Trial Phase 1 study, sponsored by Amgen.
NCT01514981 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01514981, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.
Interventions
- DRUG Placebo
- DRUG AMG 761
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Why NCT01514981 stopped before completion
NCT01514981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01514981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01514981 about?
NCT01514981 is a clinical study titled "AMG 761 in Adults With Asthma". The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.
What is the current status of trial NCT01514981?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2011-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01514981?
The interventions under investigation include: Placebo (DRUG), AMG 761 (DRUG).
Who is sponsoring clinical trial NCT01514981?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01514981's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia